Get your full text copy in PDF
Jianfeng Chu, Wei Han
(Department of Neurology, No. 1 People’s Hospital of Jining City, Jining, Shandong, China (mainland))
Med Sci Monit 2018; 24:5905-5913
DOI: 10.12659/MSM.909969
BACKGROUND:
Parkinson’s disease (PD) is a common age-related neurodegenerative disorder, but effective therapeutic agents for PD remain largely limited.
MATERIAL AND METHODS:
In the present study, we evaluated the beneficial effects and underlying mechanisms of punicalagin (PN) in human neuroblastoma SH-SY5Y cells treated with 6-hydroxydopamine (6-OHDA) to mimic PD in vitro. Cell viability was monitored by MTT assay and LDH release assay. Cell apoptosis was assayed by Annexin V-FITC/PI double-staining. Intracellular ROS production was assessed by DCFH-DA staining. The expression levels of protein and mRNA were determined by Western blotting and qRT-PCR analysis, respectively.
RESULTS:
The results showed that pretreatment of SH-SY5Y cells with PN (50, 100, and 200 µM) prior to exposure to 200 µM 6-OHDA for 2 h resulted in increased cell viability and decreased cell apoptosis. PN also inhibited excessive oxidative stress in 6-OHDA-treated SH-SY5Y cells. Moreover, PN treatment effectively restored mitochondrial function and enhanced phosphorylation of AMPK. Furthermore, PN blocked 6-OHDA-induced NF-κB activation and IL-1β expression.
CONCLUSIONS:
Our study shows that PN exhibited neuroprotective effects on the 6-OHDA-treated SH-SY5Y cells, thus providing a potential theoretical insight for the clinical application of PN against PD.